{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:08:51Z","timestamp":1788480531971,"version":"build-2803163510"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1227,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"345 Talent Project of Shengjing Hospital"},{"name":"Cardiovascular Multidisciplinary Integrated Research Fund","award":["Z-2016-23-2101-15"],"award-info":[{"award-number":["Z-2016-23-2101-15"]}]},{"name":"Liaoning Educational Committee Program","award":["JCZR2020012"],"award-info":[{"award-number":["JCZR2020012"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Left ventricular thrombus (LVT) increases the risk of thrombotic events and mortality. Vitamin K antagonists (VKAs) used to treat LVT have several known risks, as a result of which direct oral anticoagulant (DOAC) use has recently increased. We aimed to evaluate the safety and efficacy of DOACs and VKAs in treating LVT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We searched PubMed, Embase, Cochrane Library trials, and Web of Science databases for studies published before 19 April 2022, involving DOAC versus VKA treatment for patients with LVT. This meta-analysis comprised 21 studies (total patients, n = 3172; DOAC group, n = 888; VKA group, n = 2284). A statistically significant reduction in bleeding events was observed in patients on DOACs vs. those on VKAs (risk ratio (RR) = 0.73, P = 0.004). Patients on DOACs residing in North American and European regions and those with ischaemic heart disease (IHD) had a significantly lower risk of bleeding events than patients residing in other regions or those with a different LVT aetiology, respectively (RR = 0.78, P = 0.04; RR = 0.38, P = 0.02; and RR = 0.63, P = 0.009). A statistically significant reduction in stroke in patients on DOACs versus VKAs (RR = 0.72, P = 0.03) was observed, and patients on DOACs residing in North America and those with IHD had a significantly lower risk of stroke (RR = 0.73, P = 0.04, and RR = 0.61, P = 0.03, respectively). Compared with VKAs, DOACs are statistically associated with an increase in LVT resolution at 1 month (RR = 1.96, P = 0.008). No statistical between-group difference in all-cause mortality (RR = 0.72, P = 0.05), systemic embolism (RR = 0.87, P = 0.74), stroke or systemic embolism (RR = 0.90, P = 0.50), and LVT resolution at the end of follow-up (RR = 1.06, P = 0.13) was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared with VKAs, DOACs significantly reduce the risk of bleeding events and stroke in LVT patients, but mortality was similar in both groups. The advantages are apparent not only in patients belonging to the predominantly white residential areas such as North American and European regions but also in patients with LVT due to IHD. DOACs show promising effects in treating LVT compared with VKAs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14084","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T09:45:13Z","timestamp":1658915113000},"page":"3519-3532","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Systematic Review of Efficacy of Direct Oral Anticoagulants and Vitamin K Antagonists in Left Ventricular Thrombus"],"prefix":"10.1093","volume":"9","author":[{"given":"Lei","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Cardiology, Shengjing Hospital of China Medical University , Shenyang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Shengjing Hospital of China Medical University , Shenyang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilong","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shengjing Hospital of China Medical University , Shenyang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"key":"2026012114160344100_ehf214084-bib-0001","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamacardio.2018.1086","article-title":"Left ventricular thrombus after acute myocardial infarction: Screening, prevention, and treatment","volume":"3","author":"McCarthy","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026012114160344100_ehf214084-bib-0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/731936","article-title":"Prevalence and Aetiology of left ventricular thrombus in patients undergoing transthoracic echocardiography at the University of Maiduguri Teaching Hospital","volume":"2014","author":"Talle","year":"2014","journal-title":"Adv Med"},{"key":"2026012114160344100_ehf214084-bib-0003","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/1753944717711139","article-title":"Challenges in management of left ventricular thrombus","volume":"11","author":"Habash","year":"2017","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"2026012114160344100_ehf214084-bib-0004","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"2026012114160344100_ehf214084-bib-0005","first-page":"362","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"key":"2026012114160344100_ehf214084-bib-0006","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"39","author":"Ib\u00e1nez","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012114160344100_ehf214084-bib-0007","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/CIRCOUTCOMES.114.000907","article-title":"Novel oral anticoagulant use among patients with atrial fibrillation hospitalized with ischemic stroke or transient ischemic attack","volume":"8","author":"Patel","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026012114160344100_ehf214084-bib-0008","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/bcp.13299","article-title":"Trends in the prescription of novel oral anticoagulants in UK primary care","volume":"83","author":"Loo","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2026012114160344100_ehf214084-bib-0009","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2026012114160344100_ehf214084-bib-0010","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0735-1097(22)02019-8","article-title":"Widespread off-label use of direct oral anticoagulants in patients with left ventricular thrombus","volume":"79","author":"Shi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026012114160344100_ehf214084-bib-0011","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association of cardio-thoracic surgery (EACTS)","volume":"42","author":"Hindricks","year":"2020","journal-title":"Eur Heart J"},{"key":"2026012114160344100_ehf214084-bib-0012","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3389\/fphar.2019.00773","article-title":"Efficacy and safety of direct Oral anticoagulants for secondary prevention of cancer-associated thrombosis: A systematic review and meta-analysis of randomized controlled trials and prospective cohort studies","volume":"10","author":"Wang","year":"2019","journal-title":"Front Pharmacol"},{"key":"2026012114160344100_ehf214084-bib-0013","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/FJC.0000000000000826","article-title":"Direct Oral anticoagulants for the treatment of left ventricular thrombus-a new indication? A meta-summary of case reports","volume":"75","author":"Tomasoni","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026012114160344100_ehf214084-bib-0014","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jacc.2021.01.049","article-title":"Comparative study of oral anticoagulation in left ventricular thrombi (no-LVT trial)","volume":"77","author":"Abdelnabi","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026012114160344100_ehf214084-bib-0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s43044-021-00164-7","article-title":"Rivaroxaban versus warfarin for the management of left ventricle thrombus","volume":"73","author":"Albabtain","year":"2021","journal-title":"Egyptian Heart Journal"},{"key":"2026012114160344100_ehf214084-bib-0016","first-page":"57","article-title":"Apixaban versus warfarin in patients with left ventricular (LV) thrombus, a prospective randomized trial","volume":"19","author":"Alcalai","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026012114160344100_ehf214084-bib-0017","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12959-020-00242-x","article-title":"Direct oral anticoagulant use in left ventricular thrombus","volume":"18","author":"Ali","year":"2020","journal-title":"Thromb J"},{"key":"2026012114160344100_ehf214084-bib-0018","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11239-020-02371-6","article-title":"Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus","volume":"52","author":"Bass","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"2026012114160344100_ehf214084-bib-0019","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/1074248420967644","article-title":"Direct oral anticoagulants in the treatment of left ventricular thrombus: A retrospective, multicenter study and meta-analysis of existing data","volume":"26","author":"Cochran","year":"2021","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026012114160344100_ehf214084-bib-0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40261-020-00898-3","article-title":"Management of left ventricular thrombi with direct oral anticoagulants: Retrospective comparative study with vitamin K antagonists","volume":"40","author":"Daher","year":"2020","journal-title":"Clin Drug Investig"},{"key":"2026012114160344100_ehf214084-bib-0021","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.amjmed.2020.05.025","article-title":"Treatment of left ventricular thrombus with direct oral anticoagulants: A retrospective observational study","volume":"133","author":"Guddeti","year":"2020","journal-title":"Am J Med"},{"key":"2026012114160344100_ehf214084-bib-0022","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40256-022-00533-w","article-title":"Safety and effectiveness of direct Oral anticoagulants versus warfarin for treating left ventricular thrombus","volume":"22","author":"Herald","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026012114160344100_ehf214084-bib-0023","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/ehf2.12718","article-title":"Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus","volume":"7","author":"Iqbal","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114160344100_ehf214084-bib-0024","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/FJC.0000000000000987","article-title":"Evaluation of direct Oral anticoagulants versus warfarin for Intracardiac thromboses","volume":"77","author":"Iskaros","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026012114160344100_ehf214084-bib-0025","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/ehjcvp\/pvaa096","article-title":"The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction (AMI)","volume":"7","author":"Jones","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026012114160344100_ehf214084-bib-0026","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0735-1097(19)31324-5","article-title":"Contemporary etiologies, treatment strategies, and outcmes of left ventricular thrombus","volume":"73","author":"McCarthy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026012114160344100_ehf214084-bib-0027","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1007\/s11739-021-02788-8","article-title":"Direct oral anticoagulants versus warfarin for the treatment of left ventricular thrombosis","volume":"16","author":"Mihm","year":"2021","journal-title":"Intern Emerg Med"},{"key":"2026012114160344100_ehf214084-bib-0028","first-page":"45","article-title":"Left ventricular thrombus after ST segment elevation myocardial infarction: A single-Centre observational study","volume":"133","author":"Ratnayake","year":"2020","journal-title":"N Z Med J"},{"key":"2026012114160344100_ehf214084-bib-0029","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/jamacardio.2020.0652","article-title":"Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi","volume":"5","author":"Robinson","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026012114160344100_ehf214084-bib-0030","first-page":"212","article-title":"Treatment and outcomes in patients with left ventricular thrombus-experiences from the aga khan university hospital","volume":"39","author":"Varwani","year":"2021","journal-title":"Nairobi-Kenya Pan African Medical Journal"},{"key":"2026012114160344100_ehf214084-bib-0031","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1177\/1060028020975111","article-title":"Direct Oral anticoagulants versus warfarin in the treatment of left ventricular thrombus","volume":"55","author":"Willeford","year":"2021","journal-title":"Ann Pharmacother"},{"key":"2026012114160344100_ehf214084-bib-0032","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/JCPC.JCPC_41_20","article-title":"Apixaban versus warfarin in patients with left ventricular thrombus: A pilot prospective randomized outcome blinded study investigating size reduction or resolution of left ventricular thrombus","volume":"9","author":"W. Isa WY, Hwong N, Mohamed Yusof AK, Yusof Z, Loong NS, Wan-Arfah N, Naing NN.","year":"2020","journal-title":"J Clin Prev Cardiol"},{"key":"2026012114160344100_ehf214084-bib-0033","doi-asserted-by":"crossref","first-page":"9427","DOI":"10.21037\/apm-21-1683","article-title":"Direct oral anticoagulants versus vitamin K antagonists for patients with left ventricular thrombus","volume":"10","author":"Xu","year":"2021","journal-title":"Ann Palliat Med"},{"key":"2026012114160344100_ehf214084-bib-0034","article-title":"Rivaroxaban versus vitamin K antagonists (warfarin) based on the triple therapy for left ventricular thrombus after ST-elevation myocardial infarction","author":"Zhang","year":"2021","journal-title":"Heart Vessels"},{"key":"2026012114160344100_ehf214084-bib-0035","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.636491","article-title":"Safety and efficacy of vitamin K antagonists vs. novel Oral anticoagulants in patients with left ventricular thrombus: A meta-analysis","volume":"8","author":"Xuan","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2026012114160344100_ehf214084-bib-0036","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.cjco.2021.04.007","article-title":"Direct Oral anticoagulants vs vitamin K antagonists in left ventricular thrombi: A systematic review and meta-analysis","volume":"3","author":"Michael","year":"2021","journal-title":"CJC Open"},{"key":"2026012114160344100_ehf214084-bib-0037","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"2026012114160344100_ehf214084-bib-0038","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026012114160344100_ehf214084-bib-0039","author":"Ottawa Hospital Research Institute"},{"key":"2026012114160344100_ehf214084-bib-0040","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins"},{"key":"2026012114160344100_ehf214084-bib-0041","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry","volume":"61","author":"Peters","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"2026012114160344100_ehf214084-bib-0042","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1148\/rg.2021200125","article-title":"Ischemic heart disease: Noninvasive imaging techniques and findings","volume":"41","author":"Sirajuddin","year":"2021","journal-title":"Radiographics"},{"key":"2026012114160344100_ehf214084-bib-0043","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12968-018-0494-3","article-title":"Incidence and predictors of left ventricular thrombus by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: a meta-analysis","volume":"20","author":"Bulluck","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026012114160344100_ehf214084-bib-0044","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.003417","article-title":"Left ventricular thrombus formation after ST-segment-elevation myocardial infarction: Insights from a cardiac magnetic resonance multicenter study","volume":"8","author":"P\u00f6ss","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026012114160344100_ehf214084-bib-0045","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejim.2020.01.003","article-title":"Characterisation of patients with acute myocardial infarction complicated by left ventricular thrombus","volume":"74","author":"Leow","year":"2020","journal-title":"Eur J Intern Med"},{"key":"2026012114160344100_ehf214084-bib-0046","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jacc.2022.01.011","article-title":"Left ventricular thrombus following acute myocardial infarction: JACC state-of-the-art review","volume":"79","author":"Camaj","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026012114160344100_ehf214084-bib-0047","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012114160344100_ehf214084-bib-0048","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2026012114160344100_ehf214084-bib-0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104718","article-title":"Racial disparity in the prescription of anticoagulants and risk of stroke and bleeding in atrial fibrillation patients","volume":"29","author":"Tedla","year":"2020","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2026012114160344100_ehf214084-bib-0050","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/cpt.2316","article-title":"Pharmacogenetics of bleeding and thromboembolic events in direct Oral anticoagulant users","volume":"110","author":"L\u00e4hteenm\u00e4ki","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2026012114160344100_ehf214084-bib-0051","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/cts.13205","article-title":"Non-synonymous alterations in AKR7A3 and ABCA6 correlate with bleeding in aged patients treated with rivaroxaban","volume":"15","author":"Zhao","year":"2022","journal-title":"Clin Transl Sci"},{"key":"2026012114160344100_ehf214084-bib-0052","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181000","article-title":"Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study","volume":"12","author":"Sj\u00f6gren","year":"2017","journal-title":"PLoS ONE"},{"key":"2026012114160344100_ehf214084-bib-0053","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fifibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012114160344100_ehf214084-bib-0054","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fifibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114160344100_ehf214084-bib-0055","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s10654-021-00751-7","article-title":"Comparative efectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: A systematic review and meta-analysis","volume":"36","author":"Zhang","year":"2021","journal-title":"Eur J Epidemiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.14084","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.14084","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/5\/3519\/65352421\/eschf_9_5_3519.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/5\/3519\/65352421\/eschf_9_5_3519.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:19:14Z","timestamp":1769023154000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/9\/5\/3519\/8323056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":55,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,7,27]]},"published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14084","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10]]},"published":{"date-parts":[[2022,7,27]]},"assertion":[{"value":"2022-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}